MedTrace Logo

Cell Therapy in Diabetic Patients With ST-Segment Elevation Myocardial Infarction(STEMI)

NCT01307371 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2011-03-02

No results posted yet for this study

Summary

The purpose of this study is to investigate the efficacy and mechanism of bone marrow mononuclear cells (BMMNC) transplantation for diabetic and non-diabetic patients with ST-segment elevation myocardial infarction (STEMI)who have undergone percutaneous coronary intervention (PCI).

Conditions

  • Left Ventricular Function Systolic Dysfunction
  • Left Ventricular Function Diastolic Dysfunction
  • Death
  • Myocardial Reperfusion Injury

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Feng Cao, MD, PhD · Air Force Military Medical University, China

Eligibility

Min Age
25 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-03-31
Completion
2011-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01307371 on ClinicalTrials.gov